Abstract:Concurrent radiotherapy is the standard treatment of unresectable stage III non-small lung cancer (NSCLC) but with unsatisfied results. Tumor angiogenesis is one of the most important targets for novel agents’ exploration. Recombinant human endostatin, an angiogenesis blocker, has been indicated to normalize the tumor vasculature to make it more efficient for oxygen delivery, thereby provide a window of opportunity for enhanced sensitivity to radiation treatment. To evaluate the efficacy and safety of the addition of continuous intravenous infusion of recombinant human endostatin to concurrent chemoradiotherapy in inoperable stage III NSCLC, we designed this phase 2 study. This trial was approved by the institutional ethics committees of the four participating institutions. The study was registered on the website of ClinicalTrials.gov (NCT01733589).The eligible patients should meet the following criteria before treatment: untreated histologically or cytologically diagnosed NSCLC, inoperable stage IIIA or IIIB according to AJCC seventh staging system, performance score of 0 to 1, blood coagulation is normal. Patients with preexisting bleeding diatheses were excluded. All of the enrolled patients received thoracic radiation with dose of 60-66 Gy, continuous intravenous infusion of recombinant human endostain (7.5 mg/m2/24 h, 120 h, d-6-d-2, d8-d12, d22-d26, d36-d40, from the beginning of radiotherapy) and two cycles of etoposide (50 mg/m2, d1-d5, d29-d33) plus cisplatin (50 mg/m2, d1, d8, d29, d36). The primary endpoint was progression free survival (PFS) and the secondary endpoints were response, overall survival (OS), local regional free survival (LRFS) and toxicities. Calculating with 20% bilateral Z test (alpha = 0.05, beta = 0.2), 72 patients were needed. From November 2012 to June 2015, seventy-three patients were enrolled and 67 patients were assessable. Fifty-six patients were male and 11 patients were female. The median age was 59 years old. The majority (65.7%) of the patients were diagnosed as squamous cell carcinoma. Severe adverse events were observed in 2 patients (1 hemoptysis and 1 pneumonia). The most common adverse events was leucopenia (95.5%, Grade 3-4:44.8%). The complete response and partial response rate were 11.9% and 64.2%, respectively. The median follow-up time was 37.1 months (20.1-52.1 months). The median time of OS, PFS, and LRFS was 34.7 months, 13.3 months and 27.1 months respectively. The 1-, 2-, and 3-year PFS were 50.7%, 34.8%, and 28.2%, OS were 82.1%, 59.9%, and 47.7%, and LRFS were 72.7%, 54.7%, and 49.9%, respectively. The addition of continuous intravenous human recombinant endostatin to concurrent chemoradiotherapy is effective and tolerable in unresectable stage III NSCLC. Further randomized phase III study is warranted.

HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.

Continuous Intravenous Infusion of Recombinant Human Endostatin Combined with Concurrent Etoposide Plus Cisplatin and Radiotherapy for Treatment of Unresectable Stage Iii Non-Small-Cell Lung Cancer (helper): A Phase 2, Multicentre Study

P2.02-025 Continuous Intravenous Pumping Endostar Combined with Radiochemotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer

A prospective phase Ⅰ / Ⅱ study of recombinant endostatin (Endostar) combined with concurrent radio-chemotherapy in patients with unresectable stage Ⅲ non-small cell lung cancer

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer

Continuous Intravenous Infusion Recombinant Human Endostatin Combined with Concurrent Chemoradiation Therapy in Unresectable Stage III Non–small Lung Cancer—Results of a Multicenter Phase 2 Study (NCT01733589)

A PROSPECTIVE PHASE I/II STUDY OF RECOMBINANT ENDOSTATIN (ENDOSTAR) COMBINED WITH CONCURRENT CHEMORADIOTHERAPY IN PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER: A PRELIMINARY REPORT

Endostar in Combination with Radiotherapy and Paclitaxel/Carboplatin in Patients with Unresectable Non-Small Cell Lung Cancer of Stage Iii: Preliminary Results of A Phase Ii Study

Long‐term Results of a Randomized, Double‐blind, and Placebo‐controlled Phase III Trial: Endostar (rh‐endostatin) Versus Placebo in Combination with Vinorelbine and Cisplatin in Advanced Non‐small Cell Lung Cancer

Randomized Phase Ii Study of Recombinant Human Endostatin in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer (Nct00912392).

Endostar, an Antiangiogenesis Inhibitor, Combined with Chemoradiotherapy for Locally Advanced Cervical Cancer

Endostar Combined with Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Locoregionally Advanced Nasopharyngeal Carcinoma (LA-NPC): A Phase III, Prospective, Randomised-Controlled, Multicenter Clinical Trial.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

Platinum-based chemotherapy combined with endostar in the treatment of advanced NSCLC: A real world study.

A Multicenter, Open-Label, Randomized Phase II Controlled Study of Rh-Endostatin (endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer.

A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC

Efficacy and Safety of Endostar in the Treatment of Advanced Lung Squamous Cell Carcinoma.

Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

Update of A Phase Iii Trial of Adjuvant Vinorelbine Plus Cisplatin (np) Versus Np Plus Endostar (npe) in Patients with Completely Resected Stage Ib-Iiia Non-Small Cell Lung Cancer (Nsclc)